Conditions: Weight Gain Disorder of Bone Density and Structure, Unspecified Uterine Bleeding
Keywords: Birth Control Contraceptive Methods Female Contraception Weight Gain Bone Density
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 34
Healthy volunteers: yes

Brief summary:
The investigators are doing this study to look at how different doses of the Depot medroxyprogesterone acetate (DMPA) shot effect weight gain and bone mineral density in teens. The investigators hope that what the investigators learn from this study will be used to develop ways to keep girls from gaining weight or losing bone density when receiving DMPA.

Detailed description:
Depot medroxyprogesterone acetate (DMPA) is a generic form of the DepoProvera® shot. When receiving the birth control shot some girls gain a lot of weight while others do not. Some girls also lose bone mineral density (BMD). Bone mineral density is the amount of weight and thickness of the bones.

In this study 1 of 3 doses of DMPA will be given as an injection into the muscle in the arm. The 150mg dose is approved for use in this age group by the Food and Drug Administration (FDA) when given into the muscle. The 104mg dose is approved for use in this age group by the FDA only when given under the skin therefore it is considered experimental. The 75mg dose is also considered experimental as this dose is not FDA approved regardless of how it is given.

Arms:
arm 1: Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM arm 2: Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM arm 3: Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM

Interventions: intervention 1: Depot medroxyprogesterone acetate (DMPA)
Intervention descriptions: intervention 1: 75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months

Protocol document: